PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 27, 2024JAIDS Journal of Acquired Immune Deficiency Syndromes29 citationsOpen Access

Identifying Implementation Determinants and Strategies for Long-Acting Injectable Cabotegravir-Rilpivirine in People with HIV Who Are Virally Unsuppressed

View Full Paper
MHMatthew D. HickeyJGJanet GrochowskiFMFrancis Mayorga‐Munoz

Key Points

Key points are not available for this paper at this time.

Abstract

Early evidence suggests long-acting injectable cabotegravir and rilpivirine (LA-CAB/RPV) may be beneficial for people with HIV (PWH) who are unable to attain viral suppression (VS) on oral therapy. Limited guidance exists on implementation strategies for this population.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hickey et al. (2024) studied this question.

synapsesocial.com/papers/68e720ddb6db64358769b099https://doi.org/10.1097/qai.0000000000003421
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Viral Rebound Among Persons With Diagnosed HIV Who Achieved Viral Suppression, United States2020 · 34 citations
  2. 2For Many Served By The Ryan White HIV/AIDS Program, Disparities In Viral Suppression Decreased, 2010–142017 · 46 citations
  3. 3The Golden Compass Program: Overview of the Initial Implementation of a Comprehensive Program for Older Adults Living with HIV2020 · 25 citations
  4. 4Latent Class Analysis of Syndemic Factors Associated with Sustained Viral Suppression among Ryan White HIV/AIDS Program Clients in Miami, 20172021 · 8 citations
  5. 5Housing Status, Medical Care, and Health Outcomes Among People Living With HIV/AIDS: A Systematic Review2015 · 420 citations